Forward single‐cell sequencing into clinical application: Understanding of ageing and rejuvenation from clinical observation to single‐cell solution. Issue 2 (6th May 2022)

• Record Type: Journal Article
• Authors: Yan, Furong; Li, Zhangping; Powell, Charles A.; Wang, Xiangdong
• Is Part Of: Clinical and translational discovery. Volume 2:Issue 2(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-05-06
• Subjects: cancer -- cell identity -- microenvironment -- scRNA‐seq -- transcriptomics; Medicine -- Periodicals; Medicine; Periodicals; 616
• DOI: 10.1002/ctd2.50
• Languages: English
• ISSNs: 2768-0622

Abstract

Abstract: Ageing is the part of natural biology lifespan and living pathology healthspan that is associated with impact from stress, environmental changes and diseases. The present Editorial emphasises the understanding of ageing biology and potential impact of rejuvenating interventions as a critical focus of clinical and translational medicine. The discovery and development of ageing‐associated biomarkers and therapeutic targets require understanding of the complexity of molecular metabolisms, immune responses and genetic regulations associated with ageing and rejuvenation. Transcriptomic patterns of circulating immune cells, red blood cells and platelets at single‐cell solution can be an important window to molecular mechanisms of ageing initiation and development. As part of programmes, deep understanding of ageing and rejuvenation correlations of clinical with single‐cell transcriptomics will provide more innovative opportunities to translate single‐cell RNA sequencing (scRNA‐seq) to clinical application. Abstract : Currently under development COVID‐19 vaccines still have a long way to go and be available in sufficient supply to cover the whole global population at the same time to confer the much‐needed and touted 'herd immunity', whereas BCG is readily available, which can be scaled up at a lower cost to provide the needed respite to vulnerable populations, especially in poor countries.